|
|
|
|
|||||
|
|
|
It reported robust sales of an AI-focused product.
That clutch of orders surpassed its Sonoma take for the entire previous quarter.
News of a new and lucrative set of orders for artificial intelligence (AI) processor diagnostic products boosted Aehr Test Systems' (NASDAQ: AEHR) share price on Thursday. It also helped divert investor attention away from a fairly lackluster quarterly earnings report published by the company.
Aehr announced that it had received a series of orders from multiple customers for its Sonoma AI diagnostic systems. All told, those orders total over $5.5 million. It did not identify those clients, saying only they were "leading-edge AI companies," and a "premier Bay Area lab."
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Image source: Getty Images.
Aehr didn't hesitate to mention that this set of Sonoma orders in its current (third) quarter to date already exceeds the total for the product in all of the previous quarter.
Speaking of that period, Aehr released its second-quarter fiscal 2026 results. Its net revenue sank on a year-over-year basis to $9.9 million from $13.5 million. On the bottom line, the company flipped to a net loss not in accordance with generally accepted accounting principles (GAAP) of $1.3 million, or $0.04 per share, against the year-ago profit of $700,000.
Any disappointment investors felt about these numbers was mitigated, to an extent, by Aehr's reinstatement of its guidance; it had stopped providing such projections last summer, beginning with its fourth quarter of fiscal 2025 results.
The company said it's expecting revenue of $25 million to $30 million, and a non-GAAP (adjusted) net loss of $0.05 to $0.09 per share for the second half of this fiscal year.
News of those fresh orders is definitely encouraging, but I think investors should curb their enthusiasm somewhat. It feels to me that Aehr should be doing better already, given the insatiably strong demand for AI technology. I'd hold off on buying it until it can prove that it can grow its fundamentals consistently.
Before you buy stock in Aehr Test Systems, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Aehr Test Systems wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $488,222!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,134,333!*
Now, it’s worth noting Stock Advisor’s total average return is 969% — a market-crushing outperformance compared to 196% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of January 9, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
| Jan-09 | |
| Jan-09 | |
| Jan-09 | |
| Jan-09 | |
| Jan-09 | |
| Jan-08 | |
| Jan-08 | |
| Jan-08 | |
| Jan-08 | |
| Jan-08 | |
| Jan-07 | |
| Jan-06 | |
| Jan-02 | |
| Dec-30 | |
| Dec-30 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite